RNAZ TransCode Therapeutics Inc.

FDA Catalyst Company
2.14
+0.07  (+4%)
Previous Close 2.07
Open 2.04
52 Week Low 1.95
52 Week High 7
Market Cap $27,821,892
Shares 12,977,234
Float 8,773,793
Enterprise Value $31,245,022
Volume 6,524
Av. Daily Volume 17,508
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress.

    TransCode co-founder and Chief Technology Officer, Dr. Zdravka Medarova, indicated, "We believe we remain on track to submit an exploratory Investigational New Drug Application (eIND) this year to test our lead therapeutic candidate, TTX-MC138, in a Phase 0 study in cancer patients with advanced solid tumors. We believe this study has the potential to establish proof-of-mechanism for our platform which ultimately could help us build a broad and diverse pipeline of therapeutics…

    View Full Article
  2. BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its Co-Founder and Chief Technology Officer, Dr. Zdravka Medarova, will moderate the 7th Annual RNA Medicine Symposium (RNAMEDICINE2022), co-sponsored by the Harvard Medical School (HMS) Initiative for RNA Medicine (HIRM) and the Cancer Center at Beth Israel Deaconess Medical Center, on April 28, 2022. Dr. Medarova will be moderating in her capacity as an HIRM faculty member and Associate Professor at HMS.

    "It is a great honor to be one of the moderators for this important annual event that brings together leading investigators in the field of RNA…

    View Full Article
  3. BOSTON, March 31, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for 2021 and recent business progress.

    "2021 was a foundational year for TransCode, highlighted by our successful IPO on Nasdaq in July," said Michael Dudley, co-founder, president and CEO of TransCode. "With resources from the IPO, as well an important Small Business Innovation Research (SBIR) grant, we drove significant progress across the organization, including key additions to our team that bring valuable expertise, and continued advancement of our lead candidate and our preclinical development programs. We are now building on this foundation…

    View Full Article
  4. BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an interview with Co-Founder, President and CEO, Michael Dudley, will air on The RedChip Money Report® on Bloomberg TV on March 26 at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

    The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. The RedChip Money Report® delivers insightful commentary on small-cap investing, interviews with Wall Street analysts…

    View Full Article
  5. BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. The article was published on March 21, 2022.

    The article describes the development, challenges, and clinical successes of short RNA-based drugs and details several examples of how these RNA drugs are designed, chemically modified, and delivered for treatment of cancer, cardiovascular disease, and rare genetic disorders…

    View Full Article
View All TransCode Therapeutics Inc. News